Day: February 27, 2024

AUSTIN, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) — Open Lending Corporation (Nasdaq: LPRO) (the “Company” or “Open Lending”), an industry trailblazer in lending enablement and risk analytics solutions for financial institutions, today reported financial results for its fourth quarter and full year ended December 31, 2023. “We exceeded the high-end of our guidance range for certified loans and revenues in the fourth quarter, excluding a negative change in estimate associated with our profit share. In 2023, we continued to improve our product and technology and further refined our go-to-market strategy to position us well for growth,” said Keith Jezek, CEO of Open Lending. “In 2024, our priorities will be to optimize the core business as well as further expand into the bank segment. I believe our value proposition to the various players...

Fourth quarter 2023 net sales of Qelbree® increased 97% to $46.4 million compared to fourth quarter 2022; Full year 2023 net sales of Qelbree increased 129% to $140.2 million compared to full year 2022. Fourth quarter 2023 net sales of GOCOVRI® increased 10% to $32.0 million compared to fourth quarter 2022; Full year 2023 net sales of GOCOVRI increased 15% to $119.6 million compared to full year 2022. Full year 2023 total revenues (GAAP) were $607.5 million; Full year 2023 total revenues excluding Trokendi XR® net product sales (non-GAAP)(1) increased 26% compared to full year 2022. Full year 2023 operating loss (GAAP) was $(5.3) million; Full year 2023 operating earnings (non-GAAP)(2), were $125.1 million. Full year 2024 total revenue (GAAP) guidance of $580 million to $620 million and operating earnings (non-GAAP)(3) guidance of $80 million...

Business, operational, and financial update call scheduled for 4:30 p.m. ET today LOUISVILLE, Colo., Feb. 27, 2024 (GLOBE NEWSWIRE) — Solid Power, Inc. (Nasdaq: SLDP), a leading developer of solid-state battery technology, today announced its operational and financial results for the full year 2023 and provided its outlook and objectives for 2024. Recent Business Highlights        Achieved electrolyte production capability of 1.1 metric tons per month. Ongoing electrolyte sampling program yielding positive momentum. Deepened relationship with SK On through three new agreements. Announced $50 million share repurchase authorization.“Solid Power delivered on several key strategic milestones in 2023, which strengthened our operational, technological, and competitive positioning,” said John Van Scoter, President and Chief Executive...

Fourth Quarter 2023 Financial HighlightsRevenue of $341.6 million Net income to common stockholders of $6.0 million Adjusted EBITDA(1) of $48.2 million Basic and diluted net income per share of $0.04 Adjusted diluted net income per share(1) of $0.21 $49.9 million of 45X benefit earned for 2023 torque tube deliveries; $9.3 million recognized during 2023 in the statement of operationsFull Year 2023 Financial HighlightsRevenue(2) of $1,576.6 million Net income to common stockholders of $85.5 million Adjusted EBITDA(1) of $288.1 million Basic and diluted net income per share of $0.57 and $0.56 Adjusted diluted net income per share(1) of $1.13 Cash Flow from Operating Activities of $232.0 million Free Cash Flow(3) of $215.0 million Executed contracts and awarded orders at December 31, 2023 totaling $1.8 billionALBUQUERQUE, N.M., Feb....

BURLINGTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) — LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2023 results, announced a $0.16/share quarterly dividend and provided guidance. Q4 2023 Financial ResultsSales $48.9mm, +19% (+14% organic) vs. Q4 2022 Gross margin 68.1%, +450 bps Op. income $10.2mm, +46% Op. margin 21% Net income $8.5mm, +50% Earnings per diluted share $0.38, +49% Cash up $8.1mm sequentially to $105.1mmBovine patches (+18%), allografts (+52%), valvulotomes (+12%), carotid shunts (+16%) and distributed porcine patches drove Q4 sales. EMEA sales increased 21%, the Americas 20% and APAC 11%. The gross margin increased to 68.1% in Q4 (vs. 63.6% in Q4 2022) driven primarily by average selling price increases, as well as manufacturing efficiencies. Operating income...

Fourth Quarter Revenue Increased 37.5% Year-over-Year Fourth Quarter Revenue Less Ancillary Services Increased 42.6% Year-over-Year Company Provides First Quarter and Fiscal-Year 2024 Outlook BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) — Flywire Corporation (Nasdaq: FLYW) (“Flywire” or the “Company”) a global payments enablement and software company, today reported financial results for its fourth quarter and fiscal-year ended December 31, 2023. “Our strong fourth quarter results, which included nearly 43% year over year growth in revenue less ancillary services, capped off an exceptional year for Flywire as we continue to show strong performance across the business,” said Mike Massaro, CEO of Flywire. “We are proud of all that we have accomplished in 2023, and excited for what is ahead for Flywire, with a plan that puts up strong growth...

Recursion’s PipelineRecursion’s internal pipelineMultiple clinical programs from Recursion’s first generation platform are on track to read out Phase 2 data in H2 2024 and H1 2025 with additional second generation programs approaching IND in the near-term In-licensed a program (Target Epsilon) that emerged from our fibrosis collaboration with Bayer that represents a novel approach to treating fibrotic diseases – now entering IND-enabling studies Already incorporating causal AI models into the Recursion OS trained using data from Tempus after a mid-Q4 data partnership announcedSALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its...

Company Announces 2024 Strategic Priorities Focused on Advancement of Lomecel-B™ in Hypoplastic Left Heart Syndrome ELPIS II Phase 2 Trial of Lomecel-B™ in HLHS Continues Enrollment; Completion of Study Enrollment Anticipated in 2024 Long-term Survival Data from ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association Announced Additional Validating Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease Gross Proceeds of $6.4 Million in Equity Financing Secured in Q4 Registered Direct Offerings Company to Hold Conference Call and Webcast Today, February 27, 2023 at 5pm Eastern Time MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”),...

PONTE VEDRA, Fla., Feb. 27, 2024 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided 2024 guidance. Recent HighlightsRevenue of $62.2 million in fourth quarter 2023 increased 25% over the same period in 2022; Revenue of $187.1 million for full-year 2023 increased 32% compared to prior year and was above the high end of previously provided revenue guidance range of $182 million to $186 million Blended average revenue per Lapiplasty® procedure kit sold in fourth quarter 2023 was $6,437, a record...

Highlights:Full-year testing volume grew 35% year-over-year, or 18% ex-SneakPeek® volume. Full-year 2023 revenue of $753 million, grew 11% year-over-year driven by Prenatal (30%, 15% ex-SneakPeek), Prolaris (21%), Pharmacogenomics (9%), and Hereditary Cancer (7%). Fourth quarter GAAP operating expenses of $166 million and adjusted operating expenses of $130 million, each down 6% year-over-year. Fourth quarter GAAP cash flow from operations was $(55) million; adjusted cash flow from operations was $14 million, an increase of $10 million year-over-year. Raised net proceeds of $118 million in equity offering in November 2023. In February 2024, Myriad Genetics acquired select assets from Intermountain Precision Genomics (“IPG”), including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory. Raising...